Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates of surgery avoidance and disease-free ...

Papillary Urothelial Carcinoma (PUC), is the most prevalent form of bladder cancer in the United States. With over 81,000 new ...

Urothelial carcinoma is cancer of the urinary system. The urothelium is a kind of epithelial (protective) lining of the urinary system, which includes the urinary tract, bladder, your ureters (the ...

High cystectomy avoidance rates of 92% and 82% were seen at 12 months and 36 months 1, validating the durable response and bladder sparing effect of ANKTIVA plus BCG in this indication ANKTIVA plus ...

Urothelial cancers that are either non-invasive papillary (Ta), carcinoma in situ (CIS) flat tumors, or invade the subepithelial connective tissue (T1) are collectively termed non-muscle-invasive ...

Bladder cancer is the fourth most commonly diagnosed cancer in men in the United States and the 10th leading cause of cancer deaths. Many treatments can be used for bladder cancer, and the kind of ...

ImmunityBio, Inc. (NASDAQ:IBRX) on Monday received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ...

Oral presentation provides update from QUILT-3.032 on durable complete responses to ANKTIVA® plus BCG in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) with or ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) demonstrates efficacy ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA ® (nogapendekin alfa inbakicept-pmln) in ...